Suggested remit: To appraise the clinical and cost effectiveness of ibrutinib with obinutuzumab within its marketing authorisation for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma.
As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma . Following on from advice received from the company, the timelines for this appraisal are currently to be confirmed and therefore the appraisal is suspended. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties as and when the situation changes.
 
Status Suspended
Process STA 2018
ID number 1375

Project Team

Project lead Jenna Dilkes

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
04 October 2018 Suspended, As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma . Following on from advice received from the company, the timelines for this appraisal are currently to be confirmed and therefore the appraisal is suspended. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties as and when the situation changes.
11 June 2018 - 09 July 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
24 April 2018 In progress, DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance